Preservation of immune response during chemotherapy regimens
The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
1. A method of treating a human having cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase and b) a maintenance phase,
a) the induction phase comprising:
i) administering to the human an effective amount of a selective Cyclin Dependent Kinase 4/6 (CDK4/6) inhibitor of structure:
or a pharmaceutically acceptable salt thereof,
ii) administering to the human an effective amount of a chemotherapeutic agent, and
iii) administering to the human an effective amount of an immune checkpoint inhibitor,
wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of the chemotherapeutic agent, and
wherein the chemotherapeutic agent is cytotoxic to immune effector cells;
b) the maintenance phase comprising:
i) administering to the human at least one dose of an effective amount of the immune checkpoint inhibitor, and
wherein the maintenance phase is administered following the cessation of the induction phase.
2. The method of claim 1 wherein the immune checkpoint inhibitor is selected from the group consisting of a Programmed Cell Death-1 (PD-1) inhibitor, a Programmed Cell Death-Ligand 1 (PD-L1) inhibitor, and a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor.
3. The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.
4. The method of claim 3 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
5. The method of claim 2 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor.
6. The method of claim 5 , wherein the PD-1 inhibitor is selected from the group consisting of nivolumab, pidilizumab, and pembrolizumab.
7. The method of claim 2 , wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor.
8. The method of claim 7 , wherein the CTLA-4 inhibitor is selected from the group consisting of ipilimumab and tremelimumab.
9. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of a protein synthesis inhibitor, a DNA-damaging chemotherapeutic, an akylating agent, a topoisomerase inhibitor, an RNA synthesis inhibitor, a DNA complex binder, a thiolate alkylating agent, a guanine alkylating agent, a tubulin binder, a DNA polymerase inhibitor, an anticancer enzyme, a RAC1 inhibitor, a thymidylate synthase inhibitor, an oxazophosphorine compound, an integrin inhibitor, an antifolate, a folate antimetabolite, and a combination thereof.
10. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, floxuridine, capecitabine, gemcitabine, mytomycin, cyclophosphamide, decarbazine, abraxane, ifosfamide, topotecan, irinotecan, docetaxel, temozolomide, paclitaxel, etoposide, pemetrexed, and a combination thereof.
11. The method of claim 1 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 30 minutes or less prior to the administration of the chemotherapeutic agent.
12. The method of claim 1 , wherein the immune checkpoint inhibitor is administered to the subject every three weeks during the induction phase and maintenance phase.
13. The method of claim 1 , wherein the cancer is selected from the group consisting of small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, bladder cancer, gastroesophageal cancer, cholangiocarcinoma, cervical cancer, and soft tissue sarcoma.
14. A method of treating a human having small cell lung cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase comprising a 21-day cycle and b) a maintenance phase comprising a 21-day cycle,
a) the induction phase comprising:
i) administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof, on day 1, day 2, and day 3 of the 21-day cycle,
ii) administering to the human an effective amount of carboplatin on day 1 of the 21-day cycle,
iii) administering to the human an effective amount of etoposide on day 1, day 2, and day 3 of the 21-day cycle, and
iv) administering to the human an effective amount of atezolizumab on day 1 of the 21-day cycle;
wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of carboplatin and/or etoposide;
b) the maintenance phase comprising:
i) administering to the human an effective amount of atezolizumab on day 1 of the 21-day cycle,
wherein the maintenance phase is administered following the cessation of the induction phase.
15. The method of claim 14 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 4 hours or less prior to administration of the carboplatin and/or etoposide.
16. The method of claim 14 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 30 minutes or less prior to the administration of the carboplatin and/or etoposide.
17. The method of claim 14 , wherein the CDK4/6 inhibitor is administered intravenously at a dose of between about 220 and 260 mg/m 2 .
18. The method of claim 17 , wherein the CDK4/6 inhibitor is administered intravenously at a dose of about 240 mg/m 2 .
19. The method of claim 14 , wherein the carboplatin is administered intravenously at a dose that provides an AUC of about 5.
20. The method of claim 14 , wherein the etoposide is administered intravenously at a dose of about 100 mg/m 2 .
21. The method of claim 14 , wherein the atezolizumab is administered in a dose of about 1200 mg.
22. The method of claim 14 , wherein the induction phase is repeated at least 2 times.
23. The method of claim 14 , wherein the induction phase is repeated at least 3 times.
24. The method of claim 14 , wherein the induction phase is repeated at least 4 times.
25. The method of claim 14 , wherein the maintenance phase is repeated at least 2 times.
26. The method of claim 14 , wherein the maintenance phase is repeated at least 3 times.
27. The method of claim 14 , wherein the maintenance phase is repeated at least 4 times.
28. The method of claim 1 , wherein the maintenance phase further comprises administering to the subject an effective amount of the CDK 4/6 inhibitor.
29. The method of claim 13 , wherein the cancer is bladder cancer.
30. The method of claim 29 , wherein the immune checkpoint inhibitor is a PD-L1 inhibitor.
31. The method of claim 30 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, avelumab, and durvalumab.
32. The method of claim 31 , wherein the PD-L1 inhibitor is avelumab.
33. The method of claim 29 , wherein the chemotherapeutic agent is selected from the group consisting of gemcitabine, carboplatin, cisplatin, and a combination thereof.
34. The method of claim 13 , wherein the cancer is triple negative breast cancer.
35. The method of claim 34 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab.
36. The method of claim 35 , wherein the PD-1 inhibitor is pembrolizumab.
37. The method of claim 34 , wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, paclitaxel, carboplatin, and a combination thereof.
38. A method of treating a human having urothelial carcinoma comprising administering to the human a therapeutic regimen comprising a) an induction phase and b) a maintenance phase,
(a) the induction phase comprising:
i) administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof,
ii) administering to the human an effective amount of a chemotherapeutic agent selected from the group consisting of cisplatin, carboplatin gemcitabine, and a combination thereof,
wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of the chemotherapeutic agent;
b) the maintenance phase comprising:
i) administering to the human an effective amount of a programmed death ligand 1 (PD-L1) inhibitor, and,
ii) administering to the human an effective amount of the CDK4/6 inhibitor,
wherein the maintenance phase is administered following cessation of the induction phase.
39. The method of claim 38 , wherein the CDK4/6 inhibitor and chemotherapeutic agent are administered in a 21-day cycle.
40. The method of claim 39 , wherein the 21-day cycle is repeated four or more times.
41. The method of claim 38 , wherein the PD-L1 inhibitor is selected from the group consisting of atezolizumab, durvalumab, and avelumab.
42. The method of claim 41 , wherein the PD-L1 inhibitor is avelumab.
43. A method of treating a human having triple negative breast cancer comprising administering to the human a therapeutic regimen comprising:
i) administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof,
ii) administering to the human an effective amount of a chemotherapeutic agent selected from the group consisting of doxorubicin, cyclophosphamide, paclitaxel, carboplatin, and a combination thereof,
iii) administering to the human an effective amount of pembrolizumab, wherein the CDK4/6 inhibitor is administered 24 hours or less prior to the administration of the chemotherapeutic agent.
44. The method of claim 13 , wherein the cancer is non-small cell lung cancer.
45. The method of claim 44 , wherein the immune checkpoint inhibitor is a PD-1 inhibitor selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab.
46. The method of claim 45 , wherein the PD-1 inhibitor is pembrolizumab.
47. A method of treating a human having metastatic non-squamous non-small cell lung cancer comprising administering to the human a therapeutic regimen comprising a) an induction phase comprising a 21-day cycle and b) a maintenance phase comprising a 21-day cycle,
a) the induction phase comprising:
i) administering to the human an effective amount of a selective CDK4/6 inhibitor of structure:
or a pharmaceutically acceptable salt thereof, on day 1 of the 21-day cycle,
ii) administering to the human an effective amount of carboplatin on day 1 of the 21-day cycle,
iii) administering to the human an effective amount of pemetrexed on day 1 of the 21-day cycle, and
iv) administering to the human an effective amount of pembrolizumab on day 1 of the 21-day cycle;
wherein, during the induction phase, the CDK4/6 inhibitor is only administered 24 hours or less prior to the administration of carboplatin and/or pemetrexed;
b) the maintenance phase comprising:
i) administering to the human an effective amount of pembrolizumab on day 1 of the 21-day cycle,
wherein the maintenance phase is administered following the cessation of the induction phase.
48. The method of claim 1 , wherein, during the induction phase, the CDK4/6 inhibitor is only adminsitered about 4 hours or less prior to the administration of the chemotherapeutic agent.
49. The method of claim 38 , wherien, during the induction phase, the CDK4/6 inhibitor is only administered about 4 hours or less prior to the administration of the chemotherapeutic agent.
50. The method of claim 43 , wherein, during the induction phase, the CDK4/6 inhibitor is administered about 4 or less prior to the administration of the chemotherapeutic agent.
51. The method of claim 47 , wherein, during the induction phase, the CDK4/6 inhibitor is only administered about 4 hours or less prior to the administration of carboplatin and/or pemetrexed.